We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Glycemic Effects of Honey

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01371266
Recruitment Status : Completed
First Posted : June 10, 2011
Last Update Posted : August 13, 2015
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Honey has been used as a sweetener for centuries. Recent data indicate that honey consumption may have beneficial effects upon glucose intolerance, a health issue currently affecting 57 million Americans of every age and ethnicity. In order to evaluate the glycemic effect of honey, the investigators will carry out a human trial assessing biomarkers of blood glucose responses, insulin sensitivity, oxidative stress, and inflammatory markers. Our primary objective is to determine the glycemic effects of honey in comparison to sucrose and high fructose corn syrup (HFCS). The investigators hypothesize that honey will promote improved glucose tolerance and insulin sensitivity compared to both sucrose and high fructose corn syrup in normal glycemic and glucose intolerant adults.

Condition or disease Intervention/treatment
Pre-diabetes Dietary Supplement: Honey Dietary Supplement: High Fructose Corn Syrup 55 (HFCS 55) Dietary Supplement: CHO (sugar)

Detailed Description:

Glucose intolerance and insulin resistance are associated with the development of the metabolic syndrome and chronic diseases, including, hyperlipidemia, hypertension, obesity, and type II diabetes. Current National Institutes of Health statistics estimate that 1 in 6 Americans have insulin resistance (www.diabetes.niddk.nih.gov/dm/pubs/statistics). Insulin resistance in humans is associated with glucose intolerance, enhanced oxidative stress, inflammation and alterations in lipid profiles. Improvements in glucose tolerance are associated with improved insulin sensitivity resulting in improved inflammatory and oxidative status. Dietary modification to reduced day-long serum insulin concentration is postulated to decrease hepatic cholesterol production through inhibition of HMG CoA reductase, the rate limiting enzyme involved in cholesterol synthesis.

Maintenance of normal blood glucose is dependent on the body's ability to modulate insulin secretion in response to the glucose load consumed. Although diet may be an important factor in glucose tolerance, the role of nutritive sweeteners has not been clearly defined. Much research has been performed on the effect of dietary sugars on chronic disease risk factors, including animal studies, and human studies ranging from epidemiologic to controlled feeding trials with most of this work focused on the monosaccharides: fructose and glucose or the disaccharide, sucrose.

Little work has been done on the comparative effects of honey and other nutritive sweeteners in relation to glucose tolerance and insulin sensitivity.


Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Glycemic Effects of Honey
Study Start Date : June 2011
Primary Completion Date : December 2014
Study Completion Date : August 2015
Arms and Interventions

Arm Intervention/treatment
Active Comparator: Honey
60.7 grams daily orally times 14 days
Dietary Supplement: High Fructose Corn Syrup 55 (HFCS 55)
65.7 gram daily orally times 14 days
Dietary Supplement: CHO (sugar)
50 grams daily orally times 14 days
Active Comparator: CHO
50 grams daily orally times 14 days
Dietary Supplement: Honey
60.7 grams orally daily times 14 days
Dietary Supplement: High Fructose Corn Syrup 55 (HFCS 55)
65.7 gram daily orally times 14 days
Active Comparator: High Fructose Corn Syrup
65.7 grams daily orally times 14 days
Dietary Supplement: Honey
60.7 grams orally daily times 14 days
Dietary Supplement: CHO (sugar)
50 grams daily orally times 14 days


Outcome Measures

Primary Outcome Measures :
  1. Area under the curve glucose, response for OGTT. Glucose-120 min OGTT-AUC [ Time Frame: 15 weeks ]
    Evaluation of the effect of the treatment nutritive sweeteners on glucose tolerance.


Secondary Outcome Measures :
  1. Insulin- 120 min OGTT - AUC [ Time Frame: 15 weeks ]
    Evaluation of the effect of the treatment nutritive sweeteners on insulin sensitivity.

  2. Triglycerides - 120 min OGTT - AUC [ Time Frame: 15 weeks ]
    Evaluation of the effect of the treatment nutritive sweeteners on fat metabolism.

  3. Inflammatory Markers [ Time Frame: 15 weeks ]
    Effect of nutritive sweetener intake on systemic inflammation.

  4. Oxidative Stress Markers [ Time Frame: 15 weeks ]
    Effect of nutritive sweetener intake on systemic oxidative stress.

  5. Serum Lipids [ Time Frame: 15 weeks ]
    Effect of nutritive sweetener intake on lipid metabolism.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Men and women between 20-80 years of age.
  2. Normal Glucose Tolerance

    • Fasting glucose between ≤105 mg/dl
    • Normal body weight or overweight (BMI 18-29.9)
  3. Impaired Glucose Tolerance

    • Fasting glucose between 106-125 mg/dl
    • Overweight or obese (BMI 25 - 39.9)
  4. Willingness to comply with the demands of the experimental protocol
  5. Sedentary Lifestyle

Exclusion Criteria:

  1. Known uncontrolled disease process
  2. Diabetes mellitus
  3. Use of medications that affect glucose metabolism
  4. History of an eating disorder
  5. Pregnancy or breast feeding
  6. Inability to give consent
  7. Unwillingness or inability to consume the supplemental sugars
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01371266


Locations
United States, North Dakota
Grand Forks Human Nutrition Research Center
Grand Forks, North Dakota, United States, 58201
Sponsors and Collaborators
USDA Grand Forks Human Nutrition Research Center
Investigators
Principal Investigator: Susan K. Raatz, PhD., RD Agriculture Research Service, United States Department of Agriculture, Grand Forks Human Nutrition Research Center
More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Susan Raatz, PhD, RD, Research Nutritionist, USDA Grand Forks Human Nutrition Research Center
ClinicalTrials.gov Identifier: NCT01371266     History of Changes
Other Study ID Numbers: GFHNRC021
First Posted: June 10, 2011    Key Record Dates
Last Update Posted: August 13, 2015
Last Verified: August 2015

Keywords provided by Susan Raatz, USDA Grand Forks Human Nutrition Research Center:
Glucose intolerance
Insulin resistance
Insulin
metabolic syndrome
honey
Inflammation
oxidative stress

Additional relevant MeSH terms:
Prediabetic State
Glucose Intolerance
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperglycemia